Plasma kininogen levels in the peripheral venous blood of untreated patients with active rheumatoid disease was found to be more than twice the levels measured in healthy normal individuals or in convalescing uncomplicated fracture patients. Treatment with oral indomethacin or aspirin lowered the kininogen levels nearly to normal. Sequential studies showed that the fall in kininogen was very rapid, occurring within 1-2 hours of ingestion of drug, and was paraUelled by reduction in the clinical indices of inflammation.
Introduction
We have recently reported that in patients with seropositive rheumatoid arthritis, who have received no treatment for 48 hours, the mean plasma kininogen level was more than twice that of healthy, and non-inflamed controls [1, 2] . After indomethacin therapy for 1 week, the plasma kininogen levels of the rheumatoid patients fell to within the normal range. Indomethacin had no effect on plasma kininogen levels in healthy control subjects.
We now report results obtained from a sequential study of changes produced following the onset of indomethacin and aspirin treatment in rheumatoid patients.
Methods

Clinical
Twelve patients with seropositive rheumatoid arthritis consented to take part in this study, 4 male and 8 female with ages ranging from 26 to 74 years. The mean duration of the disease was 7 years. At the time of the study their symptoms were being controlled with a variety of agents, including aspirin, indomethacin, tolmectin, prenazone and fenoprofen. Prior to commencement of the test, treatment with anti-inflammatory agents was stopped for 48 hours. At the end of this period, blood was sampled from an arm vein for the estimation of plasma kininogen, plasma proteins, PCV and plasma drug levels. The activity of the disease was monitored using a pain index (patient's assessment on a 0-5 scale) an 'articular index' of joint tenderness and by measuring grip strength [3, 4] . The patients then commenced therapy with the test drug. During the 48-hour control period, patients received placebo indistinguishable from the test drug.
Six of the patients were given oral indomethacin, 50 mg thrice daily for 7 days followed by one further day on placebo. In three of these patients and in an additional three patients, the effect was determined of a single 50-rag dose of indomethacin on the biochemical parameters. A further three patients received 975 mg of enteric coated aspirin, four times a day for I week.
Biochemical
Plasma kininogen levels were measured using the method of Brocklehurst and Zeitlin [5] involving ethanolic precipitation of the kininogen protein which was ultimately activated using trypsin. Bradykinin-like activity was assayed using the isolated oestrous rat uterus. Kininogen concentrations represent total precursor of kinin-like activity and are stated as microgrammes bradykinin equivalent per ml of plasma (~g Bk Eq per ml) giving mean and standard deviation.
Indomethacin was measured lluorimetrically after extraction from plasma [6] .
Plasma proteins were measured using cellulose acetate electrophoresis and scanning densitometry.
Statistical significance of differences was tested the paired t-test and the Mann-Whitney 'U'-test for small numbers. Figure 1 Effect of oral indomethacin, 50 mg thrice daily on venous plasma kininogen levels in 6 rheumatoid patients. Two patients left the study after 24 hours of indomethacin therapy. The figure shows means, standard deviations and numbers of patients. All vaIues from 1 hour to 7 days were significantly lower than the placebo value (p < 0.01).
Results
Plasma kininogen in rheumatoid patients
In the nine patients included in the indomethacin study, after 48 hours of placebo administration, the mean venous plasma kininogen concentration was t 1.5 :k 1.5 ~zg Bk Eq per ml. This was just over double (p <0.01) the mean control value found in seven healthy subjects (5.6 + 1.2 ~zg Bk Eq per ml).
When placebo was replaced by indomethacin treatment (50 mg tds) in six patients ( Fig. 1 ), their mean plasma kininogen level had fallen to some 65% (p<0.01) of the initial control level by 1 hour after drug ingestion. After 4 hours the kininogen had fallen to 58% of control and after 24 hours to 56%. At this point two of the patients developed nausea and vomiting and dropped out of the study. After 7 days of indomethacin therapy, the mean plasm kininogen concentration of the four remaining patients stood at 54% of the untreated level. The indomethacin treatment was once again replaced by placebo. After a further 24 hours on placebo, the mean plasma kininogen level rose to 85% of the initial raised control value. Throughout the study the packed cell volume was not detectably altered by the presence or absence of indomethacin therapy (p > 0.05) confirming our earlier finding that the alterations in plasma kininogen were not the result of non-specific changes of plasma volume [21.
Plasma concentrations of total protein, albumin and %-globulin were also determined in these patients. It can be seen from Figure 2 that the mean plasma albumin level was unchanged during the test, lying between 3.7 and 3.8 g% at all times. The mean total plasma protein level was somewhat high throughout the test, but fell slightly by up to 6.3% at 4 hours. It was thus unlikely that the dramatic changes in plasma kininogen level were merely the result of nonspecific alterations in protein synthesis. Plasma kininogen is found in the ~2-globulin fraction of plasma. The mean ~2-globulin level was greatly raised at the start of the test (0.92+0.10 g percent) and had fallen by 15% (p<0.05) 1 hour after first ingestion of indomethacin. A maximum fall of 21.7% (p<0.01) occurred at 2 hours after first ingestion of drug. The level remained reduced until placebo treatment was recommenced at the end of the test, when the mean plasma e2-globulin level rose to 106.5% of the initial control value.
Of the clinical parameters used to follow the severity of the disease in these patients, the joint diameter and grip strength were unaltered by the changes from placebo to drug or drug back to placebo. However the two forms of pain 
Figure 3
Alterations in pain assessment produced by indomethacin therapy.
Other details as in Figure 1 .
assessment were dramatically altered by indomethacin therapy (Fig.3) . 24 hours after starting indomethacin, both the articular index of joint tenderness and the pain index had fallen in every patient the mean value dropping to less than half of the value obtained after 48 hours of placebo. The values then changed little during the 7 days of therapy but returned to the initial high levels after a further 24 hours on placebo. 
Time course of indomethacin action
The speed with which the kininogen was lowered by the indomethacin was surprising. The effect of a single dose of indomethacin on the plasma kininogen concentration was studied in six patients, three from the 8-day study plus a further 3 patients (Fig.4 ). The mean plasma kininogen level, which was high after 48 hours on placebo, fell by some 10% (p < 0.05) at only 15 minutes after ingesting indomethacin, and had fallen by 34.5% (p <0.01) at 30 minutes.
In only one patient was it possible to determine plasma levels of unbound indomethacin during the first hour following ingestion of the drug (Fig. 5) . It can be seen in this patient that there is a close relationship between the appearance of indomethacin in the circulation and the fall in plasma kininogen. After the first hour, the plasma indomethacin level falls until the next dose while the kininogen level remains reasonably constant. This explains why in the other eight patients there was no correlation between plasma indomethacin and kininogen concentrations measured between 1 hour and 7 days after the onset of therapy.
Action of aspirin
In a further three patients, treatment with 0.975 g aspirin 4 times daily was commenced at 
Figure 5
Relationship between fall in venous plasma kininogen level and appearance of indornethacin in the circulation in one rheumatoid patient after ingestion of 50 mg of the drug.
the end of the 48-hour placebo period. The initial mean plasma kininogen level was 9.18 ~zg Bk Eq per ml. 1 hour after taking aspirin the mean plasma kininogen level had fallen by 25% and after 1 week the mean level had fallen by 34.4% to 6.0 ~tg Bk Eq per ml. These changes were smaller than those produced by indomethacin.
Discussion
Synovial fluid contains all of the components of the kinin-forming system [7] [8] [9] and it is thought that they originate mainly in p!asma [9] . There is some evidence to indicate the presence of raised levels of free kinin in synovial fluids from rheumatoid patients [10, 11] when compared with those from subjects with osteoarthritis or with no inflammatory joint disease [11, 12] . However synovial kinin levels do not correlate well with the severity of the disease [11, 13] . Systemic plasma kininogen levels have been measured in rheumatoid patients undergoing therapy but did not differ from normal [9, 14] .
We have shown previously that in untreated rheumatoid patients the venous plasma kininogen level is much higher than that of healthy individuals [1, 2] . This was confirmed in the present study, after placebo treatment for 48 hours, the plasma kininogen rose to twice the healthy control level. The raised kininogen is dramatically lowered to the normal range within 2-4 hours after ingesting indomethacin or aspirin. We previously reported that the changes produced by indomethacin were not artefacts produced by interference in the assay nor were they the result of non-specific changes in plasma volume or plasma proteins [2] . This is further borne out by the present study. Plasma kininogens are found in the e2-globulin fraction of plasma and in this study, the changes in plasma kininogen are paralleled only by the changes in ~2-globulins and not in plasma albumin or total protein.
The speed with which indomethacin lowered the kininogen level was surprising, 10% of the total fall taking place by 15 minutes after ingesting the drug, and 35% of the fall taking place within 30 minutes. The decrease was related to the appearance of drug in the circulation. The mechanism of this rapid loss of kininogen is not yet known. It is unlikely to be due to activation of kinin formation since in all samples tested the free plasma kinin concentration remained within normal levels at less than 5 ng Bk Eq per ml plasma. Our studies also indicate that it is not merely due to inhibition of kininogen synthesis [2] and the rapidity of the change suggests a fairly direct mode of action.
It is interesting to speculate whether these changes have any relevance to the mode of action of the non-steriodal anti-inflammatory drugs. In this study, indomethacin caused a fairly dramatic reduction in the parameters of pain. Indomethacin is a potent inhibitor of prostaglandin synthesis [15] and it seems likely that formation of both prostaglandins and kinins is necessary for the inflammatory pain response [16] . We must now consider the possibility that the analgesic action of indomethacin in rheumatoid arthritis is the result not only of blocking the production of prostaglandins but also of limiting the increased availability of kinin precursor.
Conclusions
(1) After 48 hours of placebo treatment, the venous plasma kininogen levels of rheumatoid arthritis patients rose to twice the value in healthy controls.
(2) Therapy with indomethacin or aspirin caused a rapid fall in plasma kininogen concentration, lndomethacin produced a 35% decrease within 30 minutes.
(3) The kininogen changes were paralleled by changes in plasma a2-globulin levels but not plasma albumin or total protein.
(4) Indomethacin therapy produced a marked reduction in clinical pain assessments, placebo caused a rise. I don't have to tell you. I could show you. We have preliminary results in three patients for the effects of aspirin. I find a surprisingly rapid change, after ingestion of 975 mg of aspirin. After starting this treatment the kininogen level had fallen, and a fall at 2 hours and 1 week was only very little more.
Brune (Switzerland)
Can you please tell me, whether this was an effect of an anti-inflammatory drug, or just a pharmacokinetic problem. Did you test, e.g., probenicid, or other acidic drugs highly-bound to proteins.
Zeitlin (UK)
We have not done this yet. It is fairly difficult to manipulate the rheumatoid patients because they have to have their 48 hours offdrug therapy. At the moment we are looking at the effect of cortico-steroid on this. These drugs, as you are aware, are potent prostaglandin synthetase inhibitors, and we are now interested in looking at drug therapy in which prostaglandin synthesis would be less likely involved. With regard to your question about protein binding, this is one of the studies which we intend to do.
Numo (Italy)
Have you studied this in other conditions, such as the allergic reaction, in which these mediators are involved, using indomethecin and aspirin?
Zeitlin (UK)
If you are asking me about this particular type of change in the increase in kininogen, I have personally only seen increase in kininogen in carcinoid subjects, a long time ago, and in carcinoid syndrome there is clear evidence that kinin is formed. One of the anomolous findings at that time was that with some patients who had continuous kinin formation the kininogen, instead of falling, rose, and this I imagine, was a response to compensate for continual loss of kininogen. I personally have not experienced it in allergic or anaphylactic reactions, but I know that with G.B. West's sensitising rats, although he did not comment on it, he and his group found that kininogen was raised as sensitization progressed. They also found that kinins were formed, and this is what they commented on. There are other conditions not allergic. There has been a lot of work done in the acute inflammatory response induced in animals going back to 1967. Dr. Van Arman and Nuss showed that kininogen was raised during adjuvant arthritis in rats, and this is the interesting thing, this is the thing that we can't understand; that in rats the kininogen level is not suppressed again by anti-inflammatory therapy, sufficient to suppress the inflammation produced. This is something we are currently looking at.
